Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Study evaluates course of PTSD after diagnosis of breast cancer

A study by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) at NewYork-Presbyterian/Columbia University Medical Center, has found that nearly one in four women (23 percent) newly diagnosed with breast cancer reported symptoms consistent with post-traumatic stress disorder (PTSD) shortly after diagnosis, with increased risk among black and Asian women.

1 Mar 2013

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, and TikoMed AB announced today that an agreement has been established to investigate TikoMed´s product IBsolvMIR® in a phase II clinical trial.

28 Feb 2013

Study designs and tests 60 compounds for their ability to kill human cancer cells

Inspired by a chemical that fungi secrete to defend their territory, MIT chemists have synthesized and tested several dozen compounds that may hold promise as potential cancer drugs.

28 Feb 2013

Researchers identify second B-cell attachment receptor for Epstein-Barr virus

Epstein-Barr virus (EBV) affects more than 90 percent of the population worldwide and was the first human virus found to be associated with cancer. Now, researchers from Beth Israel Deaconess Medical Center (BIDMC) have broadened the understanding of this widespread infection with their discovery of a second B-cell attachment receptor for EBV.

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Allergan receives FDA approval for Natrelle 410 breast implant

The U.S. Food and Drug Administration today approved the Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Gel Filled Breast Implant to increase breast size (augmentation) in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age. Natrelle 410 implants are manufactured by Allergan, Inc.

20 Feb 2013

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

In 2012, The Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia & Lymphoma Society (LLS) jointly issued the MF Challenge Grant , seeking innovative approaches to reversing fibrosis in patients with myelofibrosis (MF).

15 Feb 2013

Tousled-like kinases play a key role in suppression and activation of herpesviruses

Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) hide within the worldwide human population. While dormant in the vast majority of those infected, these active herpesviruses can develop into several forms of cancer.

14 Feb 2013

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Researchers at Georgia Regents University Cancer Center are investigating a new avenue of treatment to help boost poor pancreatic cancer survival rates.

13 Feb 2013

Burkitt lymphoma risk after transplantation highlighted

Solid organ transplant recipients have a significant risk for developing Burkitt lymphoma (BL), US researchers have found.

12 Feb 2013

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

7 Feb 2013

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics, Inc. today announced the initiation of two phase I clinical trials of SGN-CD19A, one for patients with B-cell acute lymphoblastic leukemia (ALL) and one for patients with B-cell non-Hodgkin lymphomas.

6 Feb 2013

Detection of B cells may predict graft-versus-host disease

The ability to detect B cells specific to the DEAD box protein may help predict the development of chronic graft-versus-host disease in male recipients of female hematopoietic cells, according to recent findings.

5 Feb 2013

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.

5 Feb 2013

Scientists visualise molecular changes in Bax protein that force cells to die

Scientists at the Walter and Eliza Hall Institute have for the first time visualised the molecular changes in a critical cell death protein that force cells to die.

3 Feb 2013

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Seattle Genetics, Inc. today announced that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications.

1 Feb 2013

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed.

31 Jan 2013

Lymphoma News and Research

Further Reading

Study evaluates course of PTSD after diagnosis of breast cancer

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

Study designs and tests 60 compounds for their ability to kill human cancer cells

Researchers identify second B-cell attachment receptor for Epstein-Barr virus

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Allergan receives FDA approval for Natrelle 410 breast implant

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

Tousled-like kinases play a key role in suppression and activation of herpesviruses

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Burkitt lymphoma risk after transplantation highlighted

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Detection of B cells may predict graft-versus-host disease

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Scientists visualise molecular changes in Bax protein that force cells to die

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Teva terminates collaboration with CureTech

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

UIC to determine whether exercise can shorten recovery time for stem cell transplant patients

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News